Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
about
Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerationsTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchLong-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide.In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialTiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy VolunteersBronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trialTiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.TIOtropium Safety and Performance In Respimat (TIOSPIR): Analysis of Asian cohort of COPD patients.Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.Long-acting muscarinic antagonists.Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?Tiotropium/Olodaterol: A Review in COPD.Tiotropium formulations and safety: a network meta-analysisSafety of inhaled long-acting anti-muscarinic agents in COPD.Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical TrialsTiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma.Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study.Considerations in establishing bioequivalence of inhaled compounds.Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD.Response to Sharma et al.: Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies.Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products
P2860
Q28067579-168C450F-1C58-49FB-93CD-15637F9C50D1Q30620671-493F4C0C-3A8F-4531-9860-01C97D8BC8D1Q30820402-FC4C46B6-C33F-4F7C-819F-301198EBD238Q30877371-2D8322DE-F927-4093-B540-41510812C39BQ34944616-C03156C0-2D1D-4AB8-8703-8F306402FE60Q34982235-575CDB9D-8FBF-4AE7-BE85-1B521A378C4FQ35768368-45FDB679-1E7C-439B-BC2C-BCEFCAF70B60Q36158846-8518E82E-A6C8-4ABB-A598-856F9B222555Q36251424-FF7F67FD-48DF-4596-BFC8-1FC7161BA6E5Q36456873-3AAF1C0B-175B-4E7A-A8D8-1D000F32F6A4Q36802125-F2AEC86D-3539-47EB-B7A2-35FC512D02E5Q36827889-CAD87352-EE89-449D-96A9-19C67D1B5B69Q37180858-7FBAF7EB-158E-4527-8AA7-F2E965C1A6CCQ37446886-59E82DF0-96E4-4CFF-9D6E-40EEDFB4B6EDQ38258538-32D09415-4CB1-4BA6-9222-25F106D22316Q38411864-62BB401C-8007-4574-A464-93876AD096C8Q38431174-7DB5AF18-BE63-41B5-9821-EA25400171B2Q38537326-3EB4D627-8061-45A0-8762-B7868762E653Q38630770-49C1755C-2931-4C05-8913-3C3E15ADCE8DQ38673383-44ACBC7D-9499-4F23-A41D-477E07C14BB8Q39137733-E4699D60-1977-4F6D-B2C2-F1701AA6455AQ39232425-09836EA8-5A32-4FBF-91D3-500246B0C8BDQ39846504-26A31233-AE43-44FE-B498-94B6A55616BCQ41722430-0A0DDFCC-2A22-4C65-BA62-24EA917D9829Q45952249-5F6148B5-6218-4EC0-A0FC-EBC53C9F4EB1Q47666210-E750674E-EE37-4DB7-9D1C-FB85F8740B4EQ48265029-3F983A81-629F-471B-8464-A5727B7BA76DQ48333318-8CBF4254-604D-4AD3-8E10-AC5E0DDF741EQ55133367-1539E943-DA9C-464B-B306-C9320CDF92AAQ58869538-74A66829-A586-41AC-ABB2-AAC547389C46
P2860
Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@ast
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@en
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@nl
type
label
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@ast
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@en
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@nl
prefLabel
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@ast
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@en
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... obstructive pulmonary disease
@en
P2093
J A van Noord
P J G Cornelissen
V Peterkin
P2860
P304
P356
10.1002/JCPH.215
P577
2013-11-27T00:00:00Z